As of Apr 24
| +0.44 / +0.78%|
The 32 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 53.78, with a high estimate of 68.00 and a low estimate of 42.21. The median estimate represents a -5.06% decrease from the last price of 56.65.
The current consensus among 33 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.